Inside every liver cell sit hundreds of tiny structures called mitochondria. They burn fat, produce energy, and generate a byproduct called reactive oxygen species, or ROS, which in small amounts are normal but in excess can damage cells. When the liver is overwhelmed by fat, as happens in a condition called metabolic dysfunction-associated steatotic liver disease, or MASLD, those mitochondria begin to malfunction. They work harder than they should, produce too much oxidative stress, and the liver gradually accumulates inflammation and scarring.
MASLD is extremely common among people with obesity. Researchers have been studying whether a class of signaling molecules called incretins, which the gut releases after meals, can address some of the underlying cellular damage. A study published in the American Journal of Physiology: Endocrinology and Metabolism took this question a step further, asking not just whether these peptides help, but exactly what they do inside liver cell mitochondria, and whether two different peptides might work better together than either does alone.
The two peptides under study
The researchers focused on two signaling molecules. The first was a GLP-1 receptor agonist, a compound that mimics a naturally occurring gut hormone called glucagon-like peptide 1. GLP-1 is released after eating and plays roles in appetite regulation, insulin secretion, and, as more recent research suggests, inflammation in tissues like the liver.
The second was PYY3-36, a fragment of peptide YY, another hormone the gut releases after meals. PYY3-36 acts on NPY2 receptors, which are found in various tissues including the liver and brain. While GLP-1 receptor agonists have received considerable scientific attention, PYY3-36 is less studied, and the question of how it affects liver mitochondria was largely open before this work.
Study design in obese rats
The team used male Wistar rats fed a high-fat, high-fructose diet combined with a compound that induces metabolic stress, producing animals with obesity and early-stage liver disease that closely mirrors human MASLD. After eight weeks on this diet, the rats were divided into five groups: one receiving the GLP-1 receptor agonist alone, one receiving PYY3-36 alone, one receiving both together, one placed on food restriction, and a saline control group. Each treatment lasted another eight weeks.
To measure what was happening inside liver cells, the researchers used a specialized instrument called an Oroboros O2K Respirometer, which can directly measure how much oxygen mitochondria consume and how much hydrogen peroxide, a marker of oxidative stress, they emit. They also performed liver tissue staining to assess fat accumulation, inflammation, and fibrosis, and used RNA sequencing to examine which genes were turned up or down in each group.
Liver inflammation and tissue findings
Both peptides, given individually, produced statistically significant reductions in hepatic inflammation and improved the histological score that pathologists use to grade MASLD severity. The combination group showed additive effects, meaning the liver tissue looked meaningfully better in animals that received both peptides than in those that received either one alone.
The tissue staining results confirmed that lipid storage, inflammatory cell infiltration, and fibrosis markers were all reduced more in the combination group. Importantly, the food restriction group, which lost weight without receiving any peptide, did not show the same degree of improvement. This distinction is notable because it suggests the molecular effects seen in the peptide groups were not simply a result of eating less or weighing less.
Mitochondrial oxygen use and oxidative stress
The respirometry data told a nuanced story. In MASLD, mitochondria often work at an abnormally high rate, consuming excessive oxygen as the liver struggles to process the fat overload. The combination of the GLP-1 receptor agonist and PYY3-36 reduced mitochondrial oxygen consumption, suggesting the organelles were being pulled back toward a more measured operating level.
At the same time, hydrogen peroxide emission from mitochondria fell significantly in the combination group. Lower H2O2 production points to reduced oxidative stress inside liver cells, which is thought to be one of the drivers of progression from simple fat accumulation toward more serious forms of liver disease. Neither food restriction nor saline treatment produced these mitochondrial changes, reinforcing the idea that the peptides were doing something specific at the cellular level.
Gene expression changes
RNA sequencing gave the researchers a window into which biological pathways were being dialed up or down. Two major pathways stood out. First, oxidative phosphorylation, the core process by which mitochondria convert fuel into usable energy, showed downregulation of its related genes in the combination group. Second, beta oxidation, the process by which mitochondria break down fatty acids, also showed reduced gene activity.
Two specific regulators drew attention. MCAD, an enzyme central to fatty acid metabolism, and PGC-1 alpha, often called a master regulator of mitochondrial biogenesis and metabolism, were both significantly reduced by PYY3-36 treatment. The combination group showed the strongest suppression. The literature suggests that in the context of MASLD, where these pathways are often running in overdrive, moderating their activity may reduce the cellular strain that drives inflammation and scarring. The authors describe this pattern as mitochondrial modulation rather than simple suppression.
What researchers concluded
The study authors concluded that PYY3-36 potentiates, meaning it amplifies, the mitochondrial effects of the GLP-1 receptor agonist in a liver disease model. The combination produced additive improvements across histological scores, mitochondrial respiration measurements, oxidative stress markers, and gene expression data. The GLP-1 receptor agonist alone produced meaningful effects, but the addition of PYY3-36 consistently pushed outcomes further.
The finding that food restriction did not replicate these mitochondrial changes is an important mechanistic detail. It suggests that the peptides are not simply working by reducing caloric intake but are engaging specific receptor-mediated pathways in liver tissue. The researchers describe this as providing insight into possible molecular mechanisms, careful language that reflects the early-stage nature of this animal research.
This is a preclinical study in rats, and animal findings do not always translate directly to human biology. The specific doses, treatment durations, and disease model used here may differ substantially from conditions relevant to humans. Still, for researchers interested in how gut-derived peptides interact with liver cell machinery, this study adds a detailed mechanistic layer to an active and rapidly developing field.
